MIRXES-B (02629) surged over 8%, reaching an intraday high of HK$47.8 and setting a new listing record. As of the latest update, the stock was up 7.28% at HK$47.38, with a turnover of HK$14.1342 million.

On the news front, MIRXES-B announced on August 15 that its indirect wholly-owned subsidiary MiRXES PTE. LTD. has recently entered into a memorandum of understanding with PT DIASTIKA BIOTEKINDO, a company listed on the Indonesia Stock Exchange under the stock code CHEK. Under this agreement, both parties have agreed to collaborate on the registration and commercialization of molecular diagnostic tests and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia. The memorandum of understanding is valid for 12 months from the date of signing.

According to the announcement, through the partnership with PT DIASTIKA BIOTEKINDO, the group can achieve several strategic objectives: immediately enter the Indonesian market by deploying blood-based microRNA or multi-omics detection equipment for high-incidence cancers such as gastric and lung cancer through PT DIASTIKA BIOTEKINDO's existing channels; leverage Indonesia's localization policies, including tax incentives for achieving 40% localization rates, and benefit from the ASEAN-centered medical device framework for regulatory flexibility; and utilize Indonesia as a demonstration market to replicate the business model across Southeast Asia, the Middle East, North Africa, and other regions with similar cancer profiles and healthcare infrastructure, thereby achieving global scale expansion.